Multidisciplinary Approach for Progressive Xanthogranulomatous Pancreatitis: Case Report and Review of the Literature

Koji Kubota, Ataru Nakayama, Hitoshi Masuo, Kaori Takasu, Fumitoshi Karasawa, Nobumichi Takeuch

Department of Surgery, Ina Central Hospital, 1313-1 Koshirokubo, Ina, Nagano 396-8555, Japan

ABSTRACT

Xanthogranulomatous pancreatitis is an extremely rare histological subset of pancreatitis characterized by chronic destructive granulomatous inflammation. Here, we report a 23-year-old man who was found to have xanthogranulomatous pancreatitis complicated by pancreas pseudocysts that infiltrated into spleen, stomach, transverse colon and omentum. The lesion persisted through medical treatments such as dietary modification, pharmacotherapy, and endoscopic intervention. Though this is benign entity, only radical resection as a last resort cut off a chain reaction of inflammation of xanthogranulomatous pancreatitis.

INTRODUCTION

Xanthogranulomatous inflammation (XGI) is a rare pathologic entity with characteristic macroscopic and microscopic features [1]. XGI is destructive inflammatory disease affected multiple organs. Most XGIs occur in the kidney [2] and gallbladder [1, 3, 4], but the other sites such as the breast [5], intracranium [6], gastrointestinal tract [7, 8], genital organs [9], bone [10], and skin [11] were reported. XGI to the pancreas, the xanthogranulomatous pancreatitis (XGP) is an extremely rare disease. Over the past decades, only 19 cases of xanthogranulomatous pancreatitis were reported in the English literature [12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]. We herein report a case of progressive XGP, where the inflammation infiltrated into the stomach, transverse colon and spleen.

CASE REPORT

A Twenty-three-year-old Japanese man was admitted to our hospital for episodes of acute upper abdominal pain. He was diagnosed with acute pancreatitis caused by main pancreatic duct stones. The abdominal computed tomography (CT) scan on admission showed pancreatic stones in main pancreatic duct as well as duct dilation and enlarged pancreas head **(Figure 1a)**. There was no past

Received October 10th, 2017-Accepted November 1st, 2017 **Keywords** Pancreatectomy; Pancreatitis **Abbreviations** IPMT intraductal papillary mucinous tumor; XGI xanthogranulomatous inflammation; XGP xanthogranulomatous pancreatitis **Correspondence** Koji Kubota Department of Surgery, Ina Central Hospital 1313-1 Koshirokubo, Ina, Nagano 396-8555, Japan **Tel** +81-265-72-3121 **Fax** +81-265-78-2248 **E-mail** kk481011@yahoo.co.jp medical history nor family history of the pancreatic disease. Hedenied alcohol use. He was referred to University hospital for extracorporeal shock wave lithotripsy (ESWL) for stone removal followed by Endoscopic Retrograde Cholangio-Pancreatography (ERCP) with pancreatic duct stenting. He underwent total eight times of ESWL and pancreatic stones in main pancreatic duct were removed (Figure 1b). Within next two years from initial treatment, he came back total three times with pancreatitis by radiological evident pancreatics stones. ERCPs were performed same manner and stones were removed (Figures 2a, 2b). However four months after the last episode of stone pancreatitis, he developed another pancreatitis without evidence of stone in the main pancreatic duct. The pancreatic pseudocysts were evident at that time, and dilation of pancreatic duct vanished (Figure 3). The serum amylase and pancreatic-amylase level were high as $615IU/\ell$ (standard value:43-116 IU/ℓ) and 587 IU/ℓ (18-53 IU/ℓ) respectively. And amylase level in the urine was also elevated as 8,604 IU/ ℓ (<500 IU/ ℓ). Complete blood count (CBC) and Comprehensive metabolic panel with fasting glucose (CMP) were within normal limits. The mutations of all pancreatitis-associated gene CPA1 [28] was negative, and the IgG 4 level was within normal limit. We initiated medical treatment (pancreatin, camostat mesylate, trimethadione, bromhexine hydrochloride, esomeprazole magnesium hydrate) and dietary restrictions (only Elental 480g/day or fast cure). The follow up abdominal CT scan after four months, however, showed multiple pseudocysts at the tail of the pancreas that infiltrated into stomach, colon, and spleen without stone at main pancreatic duct (Figure 4). Meantime his symptom had been on and off. Six months later, follow up CT scan showed ill-defined low-density area developed adjacent to pseudocysts that involved the stomach, transverse colon, and spleen. The border between pancreas and stomach became



Figure 1. (a). Abdominal CT at first visit to our hospital showed pancreatic stone at main pancreatic duct, main pancreatic duct (MPD) dilation, and moderate enlarged pancreas head. Asterisks indicate MPD stone, arrows indicate MPD dilation. **(b).** He underwent ESWL 8 times; Left panel; MPD stone obstructed MPD. Right panel; after ESWLs 8 times, pancreatic stones at MPD were completely removed.



Figure 2. (a). He has relapsed into pancreatitis after ten months of initial treatment. Left panel; MPD stones were appeared. Right panel; MPD stones were removed again. (b). After 8 months, he had a recurrence of pancreatitis. MPD stones were removed and drainage of MPD was performed. Arrows indicate MPD stone.



Figure 3. Abdominal CT after four months of treatment third pancreatitis revealed that the pancreas pseudocysts at the pancreatic tail, around of stomach and spleen without the pancreatic stone at main pancreatic duct. Dilation of pancreatic duct vanished. Asterisks indicate pseudocyst, arrows indicate.



Figure 4. (a). Follow up abdominal CT after one month showed multiple pseudocysts at the tail of the pancreas that are extended into stomach, colon, and spleen. (b, c). Ill-defined low-density area developed around pancreas and pseudocysts involved the stomach, transverse colon, and spleen. The borders between the lesion and the pancreas, stomach, transverse colon and spleen were unclear. Sharps indicate stomach. Asterisks indicate transverse colon. Arrows indicate pseudocyst.

unclear (Figure 4). Esophagogastroduodenoscopy (EGD) showed hypertrophic mucosa with poor distensibility of the posterior gastric wall suggested inflammation from pancreatitis, and pancreatic pseudocysts involved stomach (Figure 5). Further restricted dietary treatment with total parental nutrition and pain management with NSAIDs and pentazocine hydrochloride were initiated but failed shortly after. At that point, we finally decided to perform a surgical intervention. Initially, our plan was to perform distal pancreatectomy with possible splenectomy, since we recognized the lesion was benign and attempted to preserve as many adjacent organs as possible. However, the whole lesion that include part of the transverse colon, spleen and the large portion of stomach was palpate like a solid mass and only en bloc resection appeared to be an option. The entire posterior walls of the stomach and transverse colon as well as spleen were severely adhered to the pancreas. We ended up to perform distal pancreatectomy up to superior mesenteric vein with splenectomy, partial resection of transverse colon with primary anastomosis and total gastrectomy with Rouxen Y reconstruction **(Figure 6)**. Gross examination of the specimen revealed the rupture of main pancreatic duct led to 5.0 cm pancreas pseudocysts with the thick wall made of dense fibrosis. The pancreas itself and pancreatic pseudocyst infiltrated to the stomach, spleen and transverse colon **(Figure 7)**. Histopathologic examination of the pancreatic tail specimen showed extensive fibrosis and infiltration of numerous foamy histocytes with scattered eosinophil, neutrophils, lymphocytes, plasma cells, indicating XGI **(Figure 8)**. The XGI lesion infiltrated into not only the pancreas parenchyma but also adjacent organs such as the stomach, transverse colon, and spleen. His postoperative course was uneventful, and he was discharged on the 22nd post-operative day. After 3 years of follow up, he is in good health without any symptom.

DISCUSSION

We reported a twenty-three-year-old man who was found to have an extremely rare entity, XGP complicated by pancreas pseudocysts infiltrated into spleen, stomach, transverse colon and omentum. Originally Goodman *et*



Figure 5. Esophagogastroduodenoscopy showed hypertrophic mucosa and poor distensibility of the posterior gastric wall caused by pancreatitis and pancreatic pseudocyst.



Figure 6. Surgical figures: Pancreas firmly adhered to spleen, stomach, transverse colon and omentum. Due to extensive infiltration, we had to performed radical resection include distal pancreatectomy up to superior mesenteric vein with splenectomy, total gastrectomy with Roux-en Y reconstruction and partial resection of transverse colon with primary anastomosis.



Figure 7. Gross examination of the specimen revealed that the rupture of main pancreatic duct led to 5.0 cm pancreas pseudocysts with the thick wall made of extensive fibrosis. The pancreas and pancreatic pseudocyst adhered firmly to the stomach and transverse colon.



Figure 8. Microscopic examination revealed extensive fibrosis and infiltration of numerous foamy cells along with scattered lymphocytes and plasma cells are noted. **(a).** Hematoxylin and Eosin stain (HE) ×20, **(b).** ×100, **(c).** ×600. high-power view of foamy histocytes with clear lipid-containing cytoplasm. **(d).** Schmorl stain; Pale blue cells are foamy cells. Blue immediate iron.

al. reported that XGI is characterized by chronic mixed inflammatory process that contains varying amounts of foamy histiocytes, inflammatory cells, fibrous reaction and sometimes accompanied by multinucleated giant cells [1]. The characteristic processes of XGP include destruction and effacement of the normal structures of the affected organ and often mimic the neoplastic process. XGI itself is also a rare condition which has been well documented mainly in the gallbladder [1, 3, 4] and kidney [2]. XGI occurs in the pancreas is so rare that only 19 cases have been reported in the English literature since Ueno *et al.* reported the first case of XGP in 1993 [12]. According to 20 case reports include our case (Table 1) [12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], their median age was 60 year (23-82), XGP occurs mainly in male patients (M:F; 15:5), the locations were evenly distributed in the pancreas (head: body: tail; 7: 6: 8). In most cases, patients presented with symptoms such as abdominal pain (14 cases, 68%) and weight loss (4 cases). Only 2 cases were diagnosed by accidental findings. The majority of cases (13/20; 65%) were misdiagnosed as a neoplasm by preoperative imaging (13/20; 65%).

The exact etiology of XGP is unknown; duct obstruction, infection and hemorrhage trigger such as XGI of gallbladder and kidney. Kim *et al.* reported mucin

produced by intraductal papillary mucinous tumor (IPMT) increased the intraductal and intracystic pressure and that a leakage of mucin into the pancreatic parenchyma produced the xanthogranulomatous changes [20]. Iyer et al. suggested that obstruction to pancreatic ducts by stones followed by secondary bacterial infection initiated the xanthogranulomatous pancreatitis without cystic lesion [13]. Ueno et al. reported that a pseudocyst formed by acute alcoholic pancreatitis and, after relapse attacks, infection and hemorrhage occurred in the pseudocyst. That elevated intracystic pressure and caused secondary xanthogranulomatous change to the pancreatic cyst wall [12]. In our case, extensive pancreatic stones caused pancreatic duct obstruction and the subsequent development of longstanding pancreatitis, which might cause xanthogranulomatous change in the pancreas.

Weidman *et al.* reported that the peculiarity of the imaging of XGP is very helpful for proper preoperative diagnosis [27]. Of note, all cases except one underwent surgery due to either preoperative diagnosis as malignant or failure of medical treatment. Although the ill-defined lesions appeared around pseudocysts by the follow up CT scan, we kept treating the lesion as the benign due to the fact the patient presented as pancreatic stone induced pancreatitis. Thus, we did not pursue further diagnostic

Table 1. Cases of XGP.

Reporter Year	Country	Sex/Age	Site	Size (cm)	Chief complain	Associated lesion	Pre-OP diagnosis	Operation
Ueno (1993)	Japan	M/42	Tail	-	Abdominal pain	Alcoholic pancreatitis Pseudocyst	pseudocyst	DP
Lyer (2004)	India	M/50	Head	3	Jaundice	Chronic pancreatitis	Malignancy	PD
Lyer (2004)	India	M/36	Tail	8	Abdominal pain Jaundice	CBD Stone chronic pancreatitis	Malignancy	DP+PG
Kamitani (2005)	Japan	M/82	Body	4	Abdominal pain	IPMC	IPMC	DP+PG
Okabayashi (2007)	Japan	M/60	Tail	-	Abdominal pain Fever UP	Alcoholic pancreatitis Pseudocyst	Pseudocyst abscess	DP
Okabayashi (2007)	Japan	M/69	Tail	-	Abdominal pain	Alcoholic pancreatitis, Pseudocyst	Abscess	DP
Shima (2008)	Japan	M/66	Body	4	Abdominal pain	Alcoholic pancreatitis	Malignancy	DP
Iso (2008)	Japan	M/82	Tail	2	Weight loss	none	IPMC	DP
Ikeura (2009)	Japan	M/73	Body	3.2	Incidental	none	SPPT	PPTP +PV resection
Uguz (2010)	Turkey	M30	Head	-	Abdominal pain	Alcoholic pancreatitis	Chronic pancreatitis	DPPR
Uguz (2010)	Turkey	F/34	Head	-	Abdominal pain	Gallstone pancreatitis	Chronic pancreatitis	DPPR
Kim (2010)	Korea	F/72	Body	1.5	Diabetes mellitus	ІРМС	Mixed type IPMN	PPPD
Kim (2011)	Korea	F/70	Head	2.2	Weight loss	none	Malignancy	PD
Nishimura (2011)	Japan	M/76	Body	5.2	Abdominal pain	none	IPMC	DP
Atreyapurapu (2015)	India	M/60	Head	-	Abdominal pain	none	Malignancy	PD
Hanna (2015)	UK	F/50	Body/Tail	14.5	Abdominal pain, Nausea	20 Units of alcohol /week	Malignancy	DP+PG
Navarro (2017)	Spain	F/80	Head	-	Abdominal pain, Weight loss	none	XGP	None conservative
Gaur (2017)	India	M/58	Head	6.1	Abdominal pain, Weight loss	none	Malignancy	PD
Weidman (2017)	USA	M/56	Tail	2.5	Incidental	none	IPMN	DP+PC
Our case	Japan	M/23	Tail	5	Abdominal pain	Acute pancreatitis	Pseudocyst	DP+TG+PC

DP distal pancreatectomy and splenectomy; DPPR duodenum-preserving pancreatic head resection; IPMC(N) intraductal papillary mucinous carcinoma (neoplasm); PC partial colectomy; PD pancreaticoduodenectomy; PPPD pyrorus preserving pyrorus preserving; PPTP pyrlorus-preserving total pancreatectomy; PG partial gastrectomy; SPPT solid pseudopapillary tumor; TG total gastrectomy

imaging nor biopsy but we might have done endoscopic ultrasound guided biopsy for confirmation that the lesion was benign. Six cases included our case (6/20; 30%) underwent surgery despite the fact that preoperative diagnosis was benign [12, 15, 19]. In these cases of XGP, they had had intractable abdominal pain for a long period of time (Average 17.8 M; 1-36 M) and persisted through medical management such as low-fat diet and pharmaceutical management. Navarro et al. avoided surgery by making the diagnosis through biopsy and reported the effectiveness of medical therapy and pharmaceutical intervention [25]. In our case, it is demonstrated that his disease overall resisted for all various treatments such as dietary treatment (low-fat diet), pharmacotherapy (antibiotic, proteinase inhibitor, NSAIDs and pentazocine hydrochloride) and endoscopic therapy (remove pancreatic calculus exploited ESWL and drainage of the MPD) for total two years four months period. Only surgical intervention can cut off a chain reaction of inflammation of XGP for pancreas and its adjacent organs. However, due to the fact that both XGI and XGP are not neoplastic entities, there is always room for debate regarding surgical intervention. In our case, the intention to avoid pancreatectomy for two years four months allows XGP to progress and end up with radical resection include total gastrectomy. Fortunately, our case has been making good progress after the surgery, and his lifestyle has been improved. He drinks alcohol occasionally post operation but no recurrence of pancreatitis for almost three years.

CONCLUSION

In summary, we report a 23-year-old man who was found to have XGP complicated by pancreas pseudocysts infiltrated into spleen, stomach, transverse colon and omentum. Although we applied multidisciplinary approach, only radical resection of the involved area reached remission of the disease. Further knowledge is warranted to establish the treatment strategy for this rare, complicated pancreatitis.

Conflict of Interests

The authors declare that they have no competing interests.

References

1. Goodman ZD, Ishak KG. Xanthogranulomatous cholecystitis. Am J Surg Pathol 1981; 5:653-9. [PMID: 7337158]

2. Addison B, Zargar H, Lilic N, Merrilees D, Rice M. Analysis of 35 cases of Xanthogranulomatous pyelonephritis. ANZ J Surg 2015; 85:150-3. [PMID: 24661744]

3. Guzmán-Valdivia G. Xanthogranulomatous cholecystitis: 15 years' experience. World J Surg 2004; 28:254-7. [PMID: 14961199]

4. Han SH, Chen YL. Diagnosis and treatment of xanthogranulomatous cholecystitis: a report of 39 cases. Cell Biochem Biophys 2012; 64:131-5. [PMID:22707297]

5. Hussain T, Elahi B, Long E, Mahapatra T, McManus PL, Kneeshaw PJ. Xanthogranulomatous inflammation involving latissimus dorsi donor site and implant breast reconstruction: case report and literature review. World J Surg Oncol 2012; 10:166. [PMID: 22906098] 6. Yamada H, Kurata H, Nomura K, Utsunomiya K, Shimizu M, Isogai Y. Adult xanthogranulomatous intracranial lesion involving familial hypercholesterolemia. Jpn J Med 1989; 28:757-61. [PMID: 2699337]

7. Kubosawa H, Yano K, Oda K, Shiobara M, Ando K, Nunomura M, et al. Xanthogranulomatousgastritis with pseudosarcomatous changes. Pathol Int. 2007; 57:291-5. [PMID: 17493178]

8. Yoon JS, Jeon YC, Kim TY, Han DS, Sohn JH, Nam KW, et al. Xanthogranulomatous inflammation in terminal ileum presenting as an appendiceal mass: case report and review of the literature. Clin Endosc 2013; 46:193-6. [PMID: 23614133]

9. Murhekar K, Majhi U, Senthilkumar AC, Sundersingh S, Sridevi V. A rare case of xanthogranulomatous oopharitis. J Cancer Res Ther 2014; 10:209-10. [PMID: 24762518]

10. Vankalakunti M, Saikia UN, Mathew M, Kang M. Xanthogranulomatous osteomyelitis of ulna mimicking neoplasm. World J Surg Oncol 2007 30; 5:46. [PMID: 17470270]

11. Satter EK, Gendernalik SB, Galeckas KJ. Diffuse xanthogranulomatousdermatitis and systemic Langerhans cell histiocytosis: A novel case that demonstrates bridging between non-Langerhans cell histiocytosis and Langerhans cell histiocytosis. J Am Acad Dermatol 2009; 60:841-8. [PMID: 19022530]

12. Ueno T, Hamanaka Y, Nishihara K, Nishida M, Nishikawa M, Kawabata A, et al. Xanthogranulomatous change appearing in the pancreas cyst wall. Pancreas 1993; 8:649-51. [PMID: 8302803]

13. Iyer VK, Aggarwal S, Mathur M. Xanthogranulomatous pancreatitis: mass lesion of the pancreas simulating pancreatic carcinoma--a report of two cases. Indian J Pathol Microbiol 2004; 47:36-8. [PMID: 15471123]

14. Kamitani T, Nishimiya M, Takahashi N, Shida Y, Hasuo K, Koizuka H. Xanthogranulomatous inflammation in terminal ileum presenting as an appendiceal mass: case report and review of the literature. AJR Am J Roentgenol 2005; 185:704-7. [PMID: 16120922]

15. Okabayashi T, Nishimori I, Kobayashi M, Sugimoto T, Kohsaki T, Okamoto K, et al. Xanthogranulomatous pancreatic abscess secondary to acute pancreatitis: two case reports. Hepatogastroenterology 2007; 54:1648-51. [PMID: 18019685]

16. Shima Y, Saisaka Y, Furukita Y, Nishimura T, Horimi T, Nakamura T, et al. Resected xanthogranulomatous pancreatitis. J Hepatobiliary Pancreat Surg 2008; 15:240-2. [PMID: 18392724]

17. Iso Y, Tagaya N, Kita J, Sawada T, Kubota K. Xanthogranulomatous lesion of the pancreas mimickingpancreatic cancer. Med Sci Monit 2008; 14:CS130-3. [PMID: 18971878]

18. Ikeura T, Takaoka M, Shimatani M, Koyabu M, Kusuda T, Suzuki R, et al. Xanthogranulomatous inflammation of the peripancreatic region mimicking pancreatic cystic neoplasm. Intern Med 2009; 48:1881-4. [PMID: 19881238]

19. Uguz A, Yakan S, Gurcu B, Yilmaz F, Ilter T, Coker A. Xanthogranulomatous pancreatitis treated by duodenum-preserving pancreatic head resection. Hepatobiliary Pancreat Dis Int 2010; 9:216-8. [PMID: 20382597]

20. Kim YN, Park SY, Kim YK, Moon WS. Xanthogranulomatous pancreatitis combined with intraductal papillary mucinouscarcinoma in situ. J Korean Med Sci 2010; 25:1814-7. [PMID: 21165301]

21. Kim HS, Joo M, Chang SH, Song HY, Song TJ, Seo JW, et al. Xanthogranulomatous pancreatitis presents as a solid tumor mass: a case report. J Korean Med Sci 2011; 26:583-6. [PMID: 21468270]

22. Nishimura M, Nishihira T, Hirose T, Ishikawa Y, Yamaoka R, Inoue H, et al. Xanthogranulomatous pancreatitis mimicking a malignant cystic tumor of the pancreas: report of a case. Surg Today 2011; 41:1310-3. [PMID: 21874438]

23. Atreyapurapu V, Keshwani A, Lingadakai R, Pai K. Xanthogranulomatous pancreatitis mimicking a malignant solid tumour. BMJ Case Rep. 2016; 30. [PMID: 27030447]

24. Hanna T, Abdul-Rahman Z, Greenhalf W, Farooq A, Neoptolemos JP. Xanthogranulomatous pancreatitis associated with a mucinous cystic neoplam. Pathol Int 2016; 66:174-176. [PMID: 26560435]

25. Navarro Navarro B, Sáez González E, Ortuño JA. Xanthogranulomatous pancreatitis: a lesion that mimics pancreatic cancer. Rev Esp Enferm Dig 2017; 109:234. [PMID: 28190364]

26. Gaur K, Mandal S, Mahajan N, Saluja S, Godhi S. Xanthogranulomatous Pancreatitis - A Rare Case Defying Clinical, Radiological and Tumor Marker Diagnostics with a Review of Literature. Turk Patoloji Derg 2017; 01385. [PMID: 28272682] 27. Becker-Weidman D, Floré B, Mortelé KJ. Xanthogranulomatous pancreatitis: A review of the imaging characteristics of this rare and often misdiagnosed lesion of the pancreas. Clin Imaging 2017; 45:12-17. [PMID: 28554050]

28. Witt H, Beer S, Rosendahl J, Chen JM, Chandak GR, Masamune A, et al. Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet 2013; 45:1216-20. [PMID: 23955596]